Verified discoveries, trials, and approvals for this cancer type. Every story separates evidence strength, regulatory status, and guideline position.
In the randomized, phase 3 PANOVA-3 trial, adding Tumor Treating Fields (TTFields) -- a wearable device that emits alternating electric fields through skin-worn arrays -- to standard chemotherapy significantly extended…
Primary source cited
Last reviewed
In this prospective cohort, plasma KRAS ctDNA positivity correlated with worse survival and higher metastatic progression, while peritoneal KRAS ctDNA positivity correlated with occult/peritoneal metastatic risk — two related but…
Primary source cited
Last reviewed
The study shows that the personalized vaccine can generate long-lived cancer-specific T-cell responses and that those responses were associated with longer recurrence-free survival in this small Phase I cohort. A…
Primary source cited
Last reviewed
In the randomized, phase 3 PANOVA-3 trial, adding Tumor Treating Fields (TTFields) -- a wearable device that emits alternating electric fields through skin-worn arrays -- to standard chemotherapy significantly extended…
Primary source cited
Last reviewed
In this prospective cohort, plasma KRAS ctDNA positivity correlated with worse survival and higher metastatic progression, while peritoneal KRAS ctDNA positivity correlated with occult/peritoneal metastatic risk — two related but…
Primary source cited
Last reviewed
The study shows that the personalized vaccine can generate long-lived cancer-specific T-cell responses and that those responses were associated with longer recurrence-free survival in this small Phase I cohort. A…
Primary source cited
Last reviewed
Regulatory approval is separate from evidence certainty and from guideline position. Approval applies only to the exact indication stated in each jurisdiction record.
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study (Journal of Clinical Oncology). DOI 10.1200/JCO-25-00746.
Applies to the exact indication stated.
In the randomized, phase 3 PANOVA-3 trial, adding Tumor Treating Fields (TTFields) -- a wearable device that emits alternating electric fields through skin-worn arrays -- to standard chemotherapy significantly extended…
Primary source cited
Last reviewed
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.